The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Key updates from the interim analysis of the FLAIR trial
In this video, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, shares some key results from the interim analysis of the Phase III FLAIR trial (ISRCTN01844152) evaluating the combination of ibrutinib plus venetoclax versus ibrutinib alone in patients with chronic lymphocytic leukemia (CLL). Prof. Hillmen highlights the rate of measurable residual disease (MRD) negative responses observed in patients, which was higher in the ibrutinib plus venetoclax arm. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
